Skip to main content
. 2022 Aug 17;13:969660. doi: 10.3389/fimmu.2022.969660

Figure 3.

Figure 3

Cytokines and CAR-T copies in 33 R/R DLBCL patients. (A, B) Changes of IL-6 and CRP levels in patients with different CRS grades after CAR-T therapy. Significant higher IL-6 and CRP levels were detected in cases with grade CRS 3 than in that cases with grade CRS 0-2 (P=0.0014 and P=0.0103 respectively two-way ANOVA, shown are means±SD; n1=7, n2=26). (C, D) Changes of IL-6 and CRP levels in patients with different responses after CAR-T therapy. Patients achieving CR during follow-up period has a lower IL-6 increase than patients without achieving CR (P=0.0029, two-way ANOVA, shown are means±SD; n1= 20, n2=13), while CRP had no difference in both groups(P=0.7588, two-way ANOVA, shown are means±SD; n1=20, n2=13). (E, F) Changes of CAR-T copies in patients with different response after CAR-T therapy. Relatively higher CAR-T copies were observed in cases that achieved CR than cases without CR within 1 month(P<0.0001, two-way ANOVA, shown are means±SD; n1=9, n2=24) or 3 months(P<0.0001, two-way ANOVA, shown are means±SD; n1=13, n2=20). Note: CR for complete remission; CRS for cytokine release syndrome; IL-6 for Interferon-6; CRP for c-reactive protein.